Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis

Philippe Pierre Robichaud; Michael Arseneault; Colleen O'Connell; Rodney J. Ouellette; Pier Jr Morin

doi:10.1016/j.neulet.2021.135813

Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis

Philippe Pierre Robichaud, Michael Arseneault, Colleen O'Connell, Rodney J. Ouellette, Pier Jr Morin

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

DNA methylation has garnered much attention in recent years for its diagnostic potential in multiple conditions including cancer and neurodegenerative diseases. Conversely, advances regarding the potential diagnostic relevance of DNA methylation status have been sparse in the field of amyotrophic lateral sclerosis (ALS) even though patients diagnosed with this condition would significantly benefit from improved molecular assays aimed at furthering the current diagnostic and therapeutic options available. This review will provide an overview of the current diagnostic approaches available for ALS diagnosis and discuss the potential clinical usefulness of DNA methylation. We will also present examples of DNA methylation as a diagnostic tool in various types of cancer and neurodegenerative conditions and expand on how circulating cfDNA methylation may be leveraged for the early detection of ALS. In general, this article will reinforce the importance of cfDNA methylation as diagnostic tools and will further highlight its clinical relevance for persons diagnosed with ALS.

Original language	English
Article number	135813
Journal	Neuroscience Letters
Volume	750
DOIs	https://doi.org/10.1016/j.neulet.2021.135813
Publication status	Published - Apr 17 2021
Externally published	Yes

Bibliographical note

Funding Information:
Experimental work on diagnostic tools relevant to ALS was supported by an ALS Canada and Brain Canada Discovery Grant awarded to COC, RJO and PJM. PPR was supported by the Mitacs Elevate postdoctoral fellowship program .

Publisher Copyright:
© 2021 Elsevier B.V.

ASJC Scopus Subject Areas

General Neuroscience

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.neulet.2021.135813

Cite this

@article{4ad87718edc740cdba908535a3a138ff,

title = "Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis",

abstract = "DNA methylation has garnered much attention in recent years for its diagnostic potential in multiple conditions including cancer and neurodegenerative diseases. Conversely, advances regarding the potential diagnostic relevance of DNA methylation status have been sparse in the field of amyotrophic lateral sclerosis (ALS) even though patients diagnosed with this condition would significantly benefit from improved molecular assays aimed at furthering the current diagnostic and therapeutic options available. This review will provide an overview of the current diagnostic approaches available for ALS diagnosis and discuss the potential clinical usefulness of DNA methylation. We will also present examples of DNA methylation as a diagnostic tool in various types of cancer and neurodegenerative conditions and expand on how circulating cfDNA methylation may be leveraged for the early detection of ALS. In general, this article will reinforce the importance of cfDNA methylation as diagnostic tools and will further highlight its clinical relevance for persons diagnosed with ALS.",

author = "Robichaud, {Philippe Pierre} and Michael Arseneault and Colleen O'Connell and Ouellette, {Rodney J.} and Morin, {Pier Jr}",

note = "Funding Information: Experimental work on diagnostic tools relevant to ALS was supported by an ALS Canada and Brain Canada Discovery Grant awarded to COC, RJO and PJM. PPR was supported by the Mitacs Elevate postdoctoral fellowship program . Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = apr,

day = "17",

doi = "10.1016/j.neulet.2021.135813",

language = "English",

volume = "750",

journal = "Neuroscience Letters",

issn = "0304-3940",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis

AU - Robichaud, Philippe Pierre

AU - Arseneault, Michael

AU - O'Connell, Colleen

AU - Ouellette, Rodney J.

AU - Morin, Pier Jr

N1 - Funding Information: Experimental work on diagnostic tools relevant to ALS was supported by an ALS Canada and Brain Canada Discovery Grant awarded to COC, RJO and PJM. PPR was supported by the Mitacs Elevate postdoctoral fellowship program . Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/4/17

Y1 - 2021/4/17

N2 - DNA methylation has garnered much attention in recent years for its diagnostic potential in multiple conditions including cancer and neurodegenerative diseases. Conversely, advances regarding the potential diagnostic relevance of DNA methylation status have been sparse in the field of amyotrophic lateral sclerosis (ALS) even though patients diagnosed with this condition would significantly benefit from improved molecular assays aimed at furthering the current diagnostic and therapeutic options available. This review will provide an overview of the current diagnostic approaches available for ALS diagnosis and discuss the potential clinical usefulness of DNA methylation. We will also present examples of DNA methylation as a diagnostic tool in various types of cancer and neurodegenerative conditions and expand on how circulating cfDNA methylation may be leveraged for the early detection of ALS. In general, this article will reinforce the importance of cfDNA methylation as diagnostic tools and will further highlight its clinical relevance for persons diagnosed with ALS.

AB - DNA methylation has garnered much attention in recent years for its diagnostic potential in multiple conditions including cancer and neurodegenerative diseases. Conversely, advances regarding the potential diagnostic relevance of DNA methylation status have been sparse in the field of amyotrophic lateral sclerosis (ALS) even though patients diagnosed with this condition would significantly benefit from improved molecular assays aimed at furthering the current diagnostic and therapeutic options available. This review will provide an overview of the current diagnostic approaches available for ALS diagnosis and discuss the potential clinical usefulness of DNA methylation. We will also present examples of DNA methylation as a diagnostic tool in various types of cancer and neurodegenerative conditions and expand on how circulating cfDNA methylation may be leveraged for the early detection of ALS. In general, this article will reinforce the importance of cfDNA methylation as diagnostic tools and will further highlight its clinical relevance for persons diagnosed with ALS.

UR - http://www.scopus.com/inward/record.url?scp=85102657398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102657398&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2021.135813

DO - 10.1016/j.neulet.2021.135813

M3 - Article

C2 - 33705931

AN - SCOPUS:85102657398

SN - 0304-3940

VL - 750

JO - Neuroscience Letters

JF - Neuroscience Letters

M1 - 135813

ER -

Circulating cell-free DNA as potential diagnostic tools for amyotrophic lateral sclerosis

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this